Skip to main content
. Author manuscript; available in PMC: 2021 Aug 21.
Published in final edited form as: ACS Chem Biol. 2020 Jul 13;15(8):2079–2086. doi: 10.1021/acschembio.0c00222

Figure 6.

Figure 6.

C8 Alkyl Cysteine Causes a Decrease in Tumor Growth in NRAS-Mutated Melanoma Xenograft Mice. (a) Schematic and timeline of in vivo melanoma xenograft intraperitoneal (IP) treatments. (b) WM3000 NRAS-mutated human melanoma xenograft mice were IP injected with either 20 mg/kg/day of 1 or 49.40 mg/kg/day (2 molar equivalents) of vehicle control. Tumor volume was measured every other day for one week for both treatment groups. Results are the mean ± SEM with n = 6. *p ≤ 0.05 (unpaired, two-tailed Student’s t test). (c) Animal weight was measured every other day for the duration of the IP treatments. (d) Liver toxicity was analyzed by assessing the alanine aminotransferase (ALT) activity in the blood samples of the xenograft mice in both treatment groups. The conditions included 49.40 mg/kg/day of vehicle control, 20 mg/kg/day of C8 alkyl cysteine (1), ALT enzyme assay positive control (+), and untreated mouse negative control (−).